Role of Interleukin-6 in the Anemia of Chronic Disease

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 5, 2009, Pages 382-388

  Raj, Dominic S C ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

anemia of chronic disease; chronic kidney disease; cytokines; end stage renal disease; interleukin 6; rheumatoid arthritis

Indexed keywords

ATLIZUMAB; ERYTHROPOIETIN; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON; RECOMBINANT INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANEMIA; ARTICLE; CHRONIC DISEASE; DISEASE DURATION; DISEASE SEVERITY; DRUG TARGETING; ERYTHROPOIESIS; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY DISEASE; IRON METABOLISM; KIDNEY FAILURE; MEDLINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANEMIA; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC;

EID: 62849089145     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.01.006     Document Type: Article

References (56)

1. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
2. Moldawer L.L., Marano M.A., Wei H., Fong Y., Silen M.L., Kuo G., et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 3 (1989) 1637-1643
3. Baer A.N., Dessypris E.N., and Krantz S.B. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Semin Arthritis Rheum 19 (1990) 209-223
4. Kishimoto T., Akira S., and Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 258 (1992) 593-597
5. Nishimoto N., Kishimoto T., and Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59 suppl I (2000) 121-127
6. Maccio A., Madeddu C., Massa D., Mudu M.C., Lusso M.R., Gramignano G., et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 106 (2005) 362-367
7. van Gameren M.M., Willemse P.H., Mulder N.H., Limburg P.C., Groen H.J., Vellenga E., et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84 (1994) 1434-1441
8. Nieken J., Mulder N.H., Buter J., Vellenga E., Limburg P.C., Piers D.A., et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 86 (1995) 900-905
9. Atkins M.B., Kappler K., Mier J.W., Isaacs R.E., and Berkman E.M. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 86 (1995) 1288-1291
10. Winton E.F., Srinivasiah J., Kim B.K., Hillyer C.D., Strobert E.A., Orkin J.L., et al. Effect of recombinant human interleukin-6 (rhIL-6) and rhIL-3 on hematopoietic regeneration as demonstrated in a nonhuman primate chemotherapy model. Blood 84 (1994) 65-73
11. Kobune M., Kohgo Y., Kato J., Miyazaki E., and Niitsu Y. Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats. Hepatology 19 (1994) 1468-1475
12. Maury C.P., Andersson L.C., Teppo A.M., Partanen S., and Juvonen E. Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro. Ann Rheum Dis 47 (1988) 972-978
13. Johnson R.A., Waddelow T.A., Caro J., Oliff A., and Roodman G.D. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74 (1989) 130-138
14. Voulgari P.V., Kolios G., Papadopoulos G.K., Katsaraki A., Seferiadis K., and Drosos A.A. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 92 (1999) 153-160
15. Means Jr. R.T., and Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80 (1992) 1639-1647
16. Ferrucci L., Guralnik J.M., Woodman R.C., Bandinelli S., Lauretani F., Corsi A.M., et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 118 (2005) 1288
17. Klausner R.D., Rouault T.A., and Harford J.B. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72 (1993) 19-28
18. Jurado R.L. Iron, infections, and anemia of inflammation. Clin Infect Dis 25 (1997) 888-895
19. Weiss G. Iron and anemia of chronic disease. Kidney Int Suppl 69 (1999) S12-S17
20. Konijn A.M., and Hershko C. Ferritin synthesis in inflammation. I. Pathogenesis of impaired iron release. Br J Haematol 37 (1977) 7-16
21. Thomas C., and Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48 (2002) 1066-1076
22. Thomas C., and Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 11 (2005) 14-23
23. Vreugdenhil G., Kroos M.J., van Eijk H.G., Lowenberg B., and Swaak A.J. Impaired iron uptake and transferrin binding by erythroblasts in the anaemia of rheumatoid arthritis. Br J Rheumatol 29 (1990) 335-339
24. Jongen-Lavrencic M., Peeters H.R., Rozemuller H., Rombouts W.J., Martens A.C., Vreugdenhil G., et al. IL-6-induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations. Clin Exp Immunol 103 (1996) 328-334
25. Beard J.L., Murray-Kolb L.E., Rosales F.J., Solomons N.W., and Angelilli M.L. Interpretation of serum ferritin concentrations as indicators of total-body iron stores in survey populations: the role of biomarkers for the acute phase response. Am J Clin Nutr 84 (2006) 1498-1505
26. Feelders R.A., Vreugdenhil G., Eggermont A.M., Kuiper-Kramer P.A., van Eijk H.G., and Swaak A.J. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 28 (1998) 520-527
27. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 113 (2004) 1251-1253
28. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
29. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
30. Lou D.Q., Lesbordes J.C., Nicolas G., Viatte L., Bennoun M., Van Rooijen N., et al. Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. Hepatology 41 (2005) 1056-1064
31. Nissenson A.R., Goodnough L.T., and Dubois R.W. Anemia: not just an innocent bystander?. Arch Intern Med 163 (2003) 1400-1404
32. Anand I.S., Kuskowski M.A., Rector T.S., Florea V.G., Glazer R.D., Hester A., et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112 (2005) 1121-1127
33. Collins A.J., Ma J.Z., Xia A., and Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32 (1998) S133-S141
34. Goicoechea M., Martin J., de Sequera P., Quiroga J.A., Ortiz A., Carreño V., et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54 (1998) 1337-1343
35. Owen W.F., and Lowrie E.G. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54 (1998) 627-636
36. Barany P., Divino Filho J.C., and Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29 (1997) 565-568
37. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Lee G.H., Nissenson A.R., and Kopple J.D. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
38. Sitter T., Bergner A., and Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 1207-1211
39. Gunnell J., Yeun J.Y., Depner T.A., and Kaysen G.A. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 (1999) 63-72
40. Beguin Y., Loo M., R'Zik S., Sautois B., Lejeune F., Rorive G., et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82 (1993) 2010-2016
41. Kalantar-Zadeh K., Luft F.C., and Humphreys M.H. Moderately high serum ferritin concentration is not a sign of iron overload in dialysis patients. Kidney Int 56 (1999) 758-759
42. Auerbach M., Ballard H., Trout J.R., McIlwain M., Ackerman A., Bahrain H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
43. Rogers J.T., Bridges K.R., Durmowicz G.P., Glass J., Auron P.E., and Munro H.N. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 265 (1990) 14572-14578
44. NKF-K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 1 (2001) S182-S238
45. Kaysen G.A. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12 (2001) 1549-1557
46. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 Suppl 7 (2001) 25-28
47. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-779
48. Wolfe F., and Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 33 (2006) 1516-1522
49. Fitzsimons E.J., and Sturrock R.D. The chronic anaemia of rheumatoid arthritis: iron banking or blocking?. Lancet 360 (2002) 1713-1714
50. Faquin W.C., Schneider T.J., and Goldberg M.A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79 (1992) 1987-1994
51. Jelkmann W., Pagel H., Wolff M., and Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50 (1992) 301-308
52. Kaltwasser J.P., Kessler U., Gottschalk R., Stucki G., and Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28 (2001) 2430-2436
53. Means Jr. R.T., Olsen N.J., Krantz S.B., Dessypris E.N., Graber S.E., Stone W.J., et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis Rheum 32 (1989) 638-642
54. Nordstrom D., Lindroth Y., Marsal L., Hafström I., Henrich C., Rantapää-Dahlqvist S., et al. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol Int 17 (1997) 67-73
55. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 350 (2004) 2167-2179
56. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Bröll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829